Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Zanubrutinib in Patients With IgG4-Related Disease
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Zanubrutinib 80 MG
Eligibility
Inclusion Criteria:
- Men or women aged 18 to 85, inclusive, at the time of initial screening
- Have histopathologically confirmed IgG4-RD in the submandibular gland and/or the
lacrimal gland confirmed by international consensus pathology criteria
- Presence of a lymphoplasmacytic infiltrate with 10 IgG4+ plasma cells per
high-power field and/or an IgG4+/IgG+ plasma cell ratio of 40%
- All women must test negative for pregnancy and agree to use a reliable method of birth
control
- No current treatment with immunosuppressive medications other than prednisone 40mg
daily (or other glucocorticoid equivalent) with stable dosing for 28 days
Exclusion Criteria:
- Unstable prescribed dose of glucocorticoids within 28 days prior to baseline
- Any treatment with a synthetic DMARD including but not limited to hydroxychloroquine,
methotrexate, leflunomide, or sulfasalazine within 28 days prior to baseline
- Any treatment with a cytotoxic or immunosuppressive drug including but not limited to
cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or
tacrolimus within 28 days prior to baseline
- Any treatment with a BTK inhibitor within 6 months before baseline
- Any treatment with a JAK inhibitor within 28 days prior to baseline
- Use of biologic agents including infliximab, abatacept, or tocilizumab within 56 days
prior to baseline
- Use of a B cell depleting therapy (such as rituximab) within 12 months prior to
baseline
- A history of, or current, inflammatory or autoimmune disease (that could affect the
interpretation of safety or efficacy outcomes) other than IgG4-related disease
- Evidence of active tuberculosis, HIV, or hepatitis B or C infection
- History of cancer other than non-melanoma skin cancer, cervical dysplasia or carcinoma
in situ (cured >1 year), prostate cancer (cured >5 years), or colon cancer (cured >5
years)
Ages Eligible for Study
18 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Angie Aberia
650-723-8516
I'm interested
Psoriasis Clinical Trials
Zanubrutinib in Patients With IgG4-Related Disease
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Zanubrutinib 80 MG
Eligibility
Inclusion Criteria:
- Men or women aged 18 to 85, inclusive, at the time of initial screening
- Have histopathologically confirmed IgG4-RD in the submandibular gland and/or the
lacrimal gland confirmed by international consensus pathology criteria
- Presence of a lymphoplasmacytic infiltrate with 10 IgG4+ plasma cells per
high-power field and/or an IgG4+/IgG+ plasma cell ratio of 40%
- All women must test negative for pregnancy and agree to use a reliable method of birth
control
- No current treatment with immunosuppressive medications other than prednisone 40mg
daily (or other glucocorticoid equivalent) with stable dosing for 28 days
Exclusion Criteria:
- Unstable prescribed dose of glucocorticoids within 28 days prior to baseline
- Any treatment with a synthetic DMARD including but not limited to hydroxychloroquine,
methotrexate, leflunomide, or sulfasalazine within 28 days prior to baseline
- Any treatment with a cytotoxic or immunosuppressive drug including but not limited to
cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or
tacrolimus within 28 days prior to baseline
- Any treatment with a BTK inhibitor within 6 months before baseline
- Any treatment with a JAK inhibitor within 28 days prior to baseline
- Use of biologic agents including infliximab, abatacept, or tocilizumab within 56 days
prior to baseline
- Use of a B cell depleting therapy (such as rituximab) within 12 months prior to
baseline
- A history of, or current, inflammatory or autoimmune disease (that could affect the
interpretation of safety or efficacy outcomes) other than IgG4-related disease
- Evidence of active tuberculosis, HIV, or hepatitis B or C infection
- History of cancer other than non-melanoma skin cancer, cervical dysplasia or carcinoma
in situ (cured >1 year), prostate cancer (cured >5 years), or colon cancer (cured >5
years)
Ages Eligible for Study
18 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Angie Aberia
650-723-8516
I'm interested
Dermatology Clinical Trials
Zanubrutinib in Patients With IgG4-Related Disease
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Zanubrutinib 80 MG
Eligibility
Inclusion Criteria:
- Men or women aged 18 to 85, inclusive, at the time of initial screening
- Have histopathologically confirmed IgG4-RD in the submandibular gland and/or the
lacrimal gland confirmed by international consensus pathology criteria
- Presence of a lymphoplasmacytic infiltrate with 10 IgG4+ plasma cells per
high-power field and/or an IgG4+/IgG+ plasma cell ratio of 40%
- All women must test negative for pregnancy and agree to use a reliable method of birth
control
- No current treatment with immunosuppressive medications other than prednisone 40mg
daily (or other glucocorticoid equivalent) with stable dosing for 28 days
Exclusion Criteria:
- Unstable prescribed dose of glucocorticoids within 28 days prior to baseline
- Any treatment with a synthetic DMARD including but not limited to hydroxychloroquine,
methotrexate, leflunomide, or sulfasalazine within 28 days prior to baseline
- Any treatment with a cytotoxic or immunosuppressive drug including but not limited to
cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or
tacrolimus within 28 days prior to baseline
- Any treatment with a BTK inhibitor within 6 months before baseline
- Any treatment with a JAK inhibitor within 28 days prior to baseline
- Use of biologic agents including infliximab, abatacept, or tocilizumab within 56 days
prior to baseline
- Use of a B cell depleting therapy (such as rituximab) within 12 months prior to
baseline
- A history of, or current, inflammatory or autoimmune disease (that could affect the
interpretation of safety or efficacy outcomes) other than IgG4-related disease
- Evidence of active tuberculosis, HIV, or hepatitis B or C infection
- History of cancer other than non-melanoma skin cancer, cervical dysplasia or carcinoma
in situ (cured >1 year), prostate cancer (cured >5 years), or colon cancer (cured >5
years)
Ages Eligible for Study
18 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Angie Aberia
650-723-8516
I'm interested
Pediatric Dermatology Clinical Trials
Zanubrutinib in Patients With IgG4-Related Disease
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Zanubrutinib 80 MG
Eligibility
Inclusion Criteria:
- Men or women aged 18 to 85, inclusive, at the time of initial screening
- Have histopathologically confirmed IgG4-RD in the submandibular gland and/or the
lacrimal gland confirmed by international consensus pathology criteria
- Presence of a lymphoplasmacytic infiltrate with 10 IgG4+ plasma cells per
high-power field and/or an IgG4+/IgG+ plasma cell ratio of 40%
- All women must test negative for pregnancy and agree to use a reliable method of birth
control
- No current treatment with immunosuppressive medications other than prednisone 40mg
daily (or other glucocorticoid equivalent) with stable dosing for 28 days
Exclusion Criteria:
- Unstable prescribed dose of glucocorticoids within 28 days prior to baseline
- Any treatment with a synthetic DMARD including but not limited to hydroxychloroquine,
methotrexate, leflunomide, or sulfasalazine within 28 days prior to baseline
- Any treatment with a cytotoxic or immunosuppressive drug including but not limited to
cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or
tacrolimus within 28 days prior to baseline
- Any treatment with a BTK inhibitor within 6 months before baseline
- Any treatment with a JAK inhibitor within 28 days prior to baseline
- Use of biologic agents including infliximab, abatacept, or tocilizumab within 56 days
prior to baseline
- Use of a B cell depleting therapy (such as rituximab) within 12 months prior to
baseline
- A history of, or current, inflammatory or autoimmune disease (that could affect the
interpretation of safety or efficacy outcomes) other than IgG4-related disease
- Evidence of active tuberculosis, HIV, or hepatitis B or C infection
- History of cancer other than non-melanoma skin cancer, cervical dysplasia or carcinoma
in situ (cured >1 year), prostate cancer (cured >5 years), or colon cancer (cured >5
years)
Ages Eligible for Study
18 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Angie Aberia
650-723-8516
I'm interested
Zanubrutinib in Patients With IgG4-Related Disease
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Zanubrutinib 80 MG
Eligibility
Inclusion Criteria:
- Men or women aged 18 to 85, inclusive, at the time of initial screening
- Have histopathologically confirmed IgG4-RD in the submandibular gland and/or the
lacrimal gland confirmed by international consensus pathology criteria
- Presence of a lymphoplasmacytic infiltrate with 10 IgG4+ plasma cells per
high-power field and/or an IgG4+/IgG+ plasma cell ratio of 40%
- All women must test negative for pregnancy and agree to use a reliable method of birth
control
- No current treatment with immunosuppressive medications other than prednisone 40mg
daily (or other glucocorticoid equivalent) with stable dosing for 28 days
Exclusion Criteria:
- Unstable prescribed dose of glucocorticoids within 28 days prior to baseline
- Any treatment with a synthetic DMARD including but not limited to hydroxychloroquine,
methotrexate, leflunomide, or sulfasalazine within 28 days prior to baseline
- Any treatment with a cytotoxic or immunosuppressive drug including but not limited to
cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or
tacrolimus within 28 days prior to baseline
- Any treatment with a BTK inhibitor within 6 months before baseline
- Any treatment with a JAK inhibitor within 28 days prior to baseline
- Use of biologic agents including infliximab, abatacept, or tocilizumab within 56 days
prior to baseline
- Use of a B cell depleting therapy (such as rituximab) within 12 months prior to
baseline
- A history of, or current, inflammatory or autoimmune disease (that could affect the
interpretation of safety or efficacy outcomes) other than IgG4-related disease
- Evidence of active tuberculosis, HIV, or hepatitis B or C infection
- History of cancer other than non-melanoma skin cancer, cervical dysplasia or carcinoma
in situ (cured >1 year), prostate cancer (cured >5 years), or colon cancer (cured >5
years)
Ages Eligible for Study
18 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Angie Aberia
650-723-8516
I'm interested
Zanubrutinib in Patients With IgG4-Related Disease
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Zanubrutinib 80 MG
Eligibility
Inclusion Criteria:
- Men or women aged 18 to 85, inclusive, at the time of initial screening
- Have histopathologically confirmed IgG4-RD in the submandibular gland and/or the
lacrimal gland confirmed by international consensus pathology criteria
- Presence of a lymphoplasmacytic infiltrate with 10 IgG4+ plasma cells per
high-power field and/or an IgG4+/IgG+ plasma cell ratio of 40%
- All women must test negative for pregnancy and agree to use a reliable method of birth
control
- No current treatment with immunosuppressive medications other than prednisone 40mg
daily (or other glucocorticoid equivalent) with stable dosing for 28 days
Exclusion Criteria:
- Unstable prescribed dose of glucocorticoids within 28 days prior to baseline
- Any treatment with a synthetic DMARD including but not limited to hydroxychloroquine,
methotrexate, leflunomide, or sulfasalazine within 28 days prior to baseline
- Any treatment with a cytotoxic or immunosuppressive drug including but not limited to
cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or
tacrolimus within 28 days prior to baseline
- Any treatment with a BTK inhibitor within 6 months before baseline
- Any treatment with a JAK inhibitor within 28 days prior to baseline
- Use of biologic agents including infliximab, abatacept, or tocilizumab within 56 days
prior to baseline
- Use of a B cell depleting therapy (such as rituximab) within 12 months prior to
baseline
- A history of, or current, inflammatory or autoimmune disease (that could affect the
interpretation of safety or efficacy outcomes) other than IgG4-related disease
- Evidence of active tuberculosis, HIV, or hepatitis B or C infection
- History of cancer other than non-melanoma skin cancer, cervical dysplasia or carcinoma
in situ (cured >1 year), prostate cancer (cured >5 years), or colon cancer (cured >5
years)
Ages Eligible for Study
18 Years - 85 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Angie Aberia
650-723-8516
I'm interested